Recently, phase I study of weekly with cisplatin irinotecan chemotherapy followed by chemo-radiotherapy in locally advanced oesophageal cancer has been reported (Ilson et al, 2003).
Although we did not measure blood cell SOD in the macaque study, the recently completed phase I study with ATN-224 (Lowndes et al, 2006) indicated that substantial and maintained inhibition of blood cell SOD was associated with haematologic toxicities.
A recently completed phase I study of patients with advanced cancer described the effect of oral vorinostat in a patient with CTCL who had failed to respond to a total of five previous systemic therapies.
Recently, a phase I study in SCCHN reported that gefitinib (250/500 mg q.d). in combination with celecoxib (200/400 mg b.i.d). is very well tolerated in patients with incurable SCCHN (Wirth et al, 2005).
Recently, a phase I study for inoperable stage III non-small-cell lung cancer was stopped after a total of six patients with grade 2 and 3 radiation pneumonitis (Lind et al, 2012).
In a recently completed phase I study, successful intraductal administration of pegylated liposomal doxorubicin was carried out in 15 of the 17 women 2 to 4 weeks prior to surgery for early stage breast cancer.
Recently, a phase I study in SCCHN reported that erlotinib (150 mg qd) in combination with bevacizumab (5, 10 and 15 mg kg−1 i.v. 3q weeks) is feasible and well tolerated in patients with recurrent/metastatic SCCHN (Mauer et al, 2004).
